Levonorgestrel News and Research

RSS

Combe announces launch of Preventeza Emergency Contraceptive and campaign

Combe Inc., the makers of Vagisil, today announced the launch of its Preventeza Emergency Contraceptive #WeAre1in2 campaign to showcase solidarity around women's reproductive rights.

6 Jul 2018

Researchers identify barriers to emergency contraception access in retail pharmacies

Efforts to remove barriers to accessing emergency contraception (EC) scored victories in 2013, when the U.S. Food and Drug Administration removed age restrictions on over-the-counter sales of the levonogestrel drug Plan B. But those who need EC can still encounter cost and availability barriers.

22 Sep 2017

Early placement of hormonal IUD does not negatively affect breastfeeding or lactation

Having a hormonal intrauterine device (IUD) implanted immediately after birth does not affect a woman's ability to lactate and breastfeed, according to new research by investigators at University of Utah Health and University of New Mexico School of Medicine.

26 Aug 2017

Oral contraceptive pills have negative impact on women's quality of life, study shows

One of the most common combined oral contraceptive pills has a negative impact on women's quality of life but does not increase depressive symptoms.

18 Apr 2017

Treating PCOS in adolescent girls may help prevent future subfertility, research suggests

In adolescent girls with polycystic ovary syndrome (PCOS), bringing the amount of abdominal visceral fat and liver fat down to normal restores ovulation, normalizes the symptoms of androgen excess, and may help prevent future subfertility, new research from Spain suggests.

4 Apr 2017

Clinical trial finds women with heavy periods can be greatly helped by GP-prescribed treatments

The largest and longest running clinical trial of medical therapies for heavy periods has found that women can be greatly helped by having treatments just from their GP, with most avoiding hospital operations.

12 Oct 2016

Hormonal contraception may increase susceptibility of women to genital infection

Women account for approximately half of all individuals living with HIV worldwide, and researchers wanted to identify the risk factors that increase susceptibility of women to genital infection.

20 Apr 2016

New study provides biological explanation for how DMPA increases risk of HIV infection

In recent years, evidence has been building that injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera or DMPA) is associated with an increased risk of HIV infection. Now a study published in the September 1st issue of mBio, an online open-access journal of the American Society for Microbiology, provides a biological explanation for the phenomenon.

2 Sep 2015

Mylan releases generic version of Seasonale Tablets in the U.S.

Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets. Mylan's partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

5 May 2015

Alternative treatment options for uterine fibroids

A 47-year-old African-American woman has heavy menstrual bleeding and iron-deficiency anemia. She reports the frequent need to urinate during the night and throughout the day. A colonoscopy is negative and an ultrasonography shows a modestly enlarged uterus with three uterine fibroids, noncancerous growths of the uterus.

24 Apr 2015

Contraception access: an interview with Pamela Weir, Chief Operating Officer, Medicines360

One of the key barriers for women to receiving highly effective and safe contraception is access, because of cost. With LILETTA™ women will have expanded access to an available IUD that is safe and effective when they need or want it...

From Medicines 360 7 Apr 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Bayer expands patient assistance program for intrauterine devices

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH (Access and Resources for Contraceptive Health) program will provide Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg and Mirena (levonorgestrel-releasing intrauterine system) 52 mg to low-income women who meet eligibility criteria.

23 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Study: IUDs, contraceptive implants remain highly effective one year beyond approved duration of use

New research indicates that hormonal intrauterine devices (IUDs) and contraceptive implants remain highly effective one year beyond their approved duration of use, according to a study at Washington University School of Medicine in St. Louis.

6 Feb 2015

Study finds unnecessary hysterectomy in 1 out of 5 cases

It is estimated that one in three women in the United States will have had a hysterectomy by the age of 60. Although the numbers of hysterectomies are decreasing, a new study of more than three thousand women in Michigan who underwent hysterectomy for benign indications reveals that alternatives to hysterectomy are being underused and that treatment guidelines are often not followed.

7 Jan 2015

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures.

20 Oct 2014

Researchers recommend iron supplementation to women with heavy menstrual bleeding

A study by researchers from Finland found that diagnosis and treatment of anemia is important to improve quality of life among women with heavy periods.

9 Jun 2014

Survey finds counterfeit and defective emergency contraceptives in Peru

A survey of emergency contraceptive pills in Peru found that 28 percent of the batches studied were either of substandard quality or falsified. Many pills released the active ingredient too slowly. Others had the wrong active ingredient. One batch had no active ingredient at all.

20 Apr 2014

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 – 10.

6 Dec 2013